Biomet Planning Two Product Introductions, One Submission In October
This article was originally published in The Gray Sheet
Executive SummaryBiomet expects to make further inroads into the spinal fixation market with the introduction of the Omega 21 rod and screw spinal fixation system in the U.S. this month, President and CEO Dane Miller, PhD, told investors at the Warburg Dillon Read Global Life Sciences Conference Sept. 29 in New York City.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.